Chemistry:Tenatoprazole
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic (CYP2C19-mediated) |
| Elimination half-life | 4.8 to 7.7 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C16H18N4O3S |
| Molar mass | 346.41 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]:22
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]:27 and again in 2012.[3]:17
Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]
See also
References
- ↑ "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003. http://www.datamonitor.com/Products/Free/Brief/BFHC0600/020BFHC0600.htm.
- ↑ "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011. http://articles.economictimes.indiatimes.com/2011-03-03/news/28650790_1_wockhardt-shares-habil-khorakiwala-cdr/2.
- ↑ 3.0 3.1 "State of New Product Development". Mitsubishi Tanabe Pharma. 8 May 2012. http://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1203.pdf.
- ↑ "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma. http://globaldocuments.morningstar.com/documentlibrary/document/8cc7dd36b1a4bcb9.msdoc/original.
- ↑ "H+/K+-ATPase inhibitors: a patent review". Expert Opinion on Therapeutic Patents 23 (1): 99–111. January 2013. doi:10.1517/13543776.2013.741121. PMID 23205582.
 |  |
